Integration of mathematical modeling and microbiome data reveals how gut microbiome components impact immune response, providing insights to optimize immunotherapy strategies.

The H3K27M mutation in diffuse midline glioma increases CD99 expression to suppress apoptosis, inhibit differentiation, and induce radioresistance, supporting using the anti-CD99 antibody 10D1 in ...

Comprehensive genomic characterization uncovers maintained and gained alterations during evolution from intestinal metaplasia to gastric cancer, which could serve as predictive biomarkers to identify ...

Normal tissues actively employ a phenomenon called cell competition to drive the elimination and replacement of less fit loser cells by fitter winner cells. This quality control mechanism promotes ...

Patients with prostate cancer and homologous recombination repair alterations face worse outcomes. Early use of PARP inhibitors, especially in BRCA -mutated cancers, is promising. However, optimal ...

The FDA today approved zopapogene imadenovec (Papzimeos; Preicgen), a viral vector-based immunotherapy for a rare condition called recurrent respiratory papillomatosis (RRP), which is characterized by ...

Major Finding: Structure-based drug design allows for the development of potent, irreversible KRASG12D inhibitors.Concept: Tri-complex formation increases reactivity of the D12 aspartic acid residue ...

Suppression of innate immune signaling in NRAS-mutant tumors results from downregulation of the cGAS–STING axis and can be reversed using SOS1 inhibitors combined with STING agonists to restrain ...

The CDC7-targeting drug SGR-2921 contributed to the deaths of two patients with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes in a phase I study, prompting ...

We appreciate the thoughtful analysis included in the letter to the editor from Antonarakis and colleagues about the purported overestimation of BRCA1/2 clonal hematopoiesis (CH) variants and the ...

Strong evidence from observational studies shows that high levels of physical activity are associated with a reduced risk of breast cancer, with a dose–response effect. Human trials and animal models ...

Abstract. On April 4, 2024, the FDA approved idecabtagene vicleucel (ide-cel) for adults with relapsed or refractory multiple myeloma after two or more prior lines of therapy, including an ...